Genomic medicine company Lucence Diagnostics has launched a joint effort with Stanford University School of Medicine to develop artificial intelligence (AI) algorithms aimed at enhancing the diagnosis and treatment of liver cancer.
The Singapore-based firm said it would be working with Stanford's Olivier Gevaert, PhD, on the project, which will use imaging and molecular data from liver cancer patients to develop software tools that can help physicians make better treatment decisions. Imaging data will be fused with sequencing data that include both cancer mutations and viral DNA, Lucence said.
The team will evaluate a dataset of more than 5,000 patients to identify image changes and patterns that are linked to diagnostic and treatment outcomes in liver cancer, according to the vendor.
